Zobrazeno 1 - 10
of 4 659
pro vyhledávání: '"Paul SA"'
Autor:
Blaze, Henri
Publikováno v:
Revue des Deux Mondes (1829-1971), 1844 Mar 01. 5(5), 837-891.
Externí odkaz:
https://www.jstor.org/stable/44689617
Autor:
Gouda MA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Stephen B; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Tian Y; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Alshawa A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Onwugaje DOC; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Albittar A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Yang Y; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Zarifa A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Yilmaz B; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Gurses S; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Sprenger A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Derbala MH; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Brink A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., How JA; Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Moyers J; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, CA, USA., Piha-Paul SA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hong DS; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Meric-Bernstam F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Patel SP; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Oliva IG; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Publikováno v:
Journal of immunotherapy and precision oncology [J Immunother Precis Oncol] 2024 Nov 01; Vol. 7 (4), pp. 247-254. Date of Electronic Publication: 2024 Nov 01 (Print Publication: 2024).
Autor:
Piha-Paul SA; Department of Investigational Cancer Therapeutics (A Phase I Clinical Trials Program), University of Texas MD Anderson Cancer Center, Houston, TX, USA. spihapau@mdanderson.org., Tseng C; Department of Investigational Cancer Therapeutics (A Phase I Clinical Trials Program), University of Texas MD Anderson Cancer Center, Houston, TX, USA., Leung CH; Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Yuan Y; Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Karp DD; Department of Investigational Cancer Therapeutics (A Phase I Clinical Trials Program), University of Texas MD Anderson Cancer Center, Houston, TX, USA., Subbiah V; Department of Investigational Cancer Therapeutics (A Phase I Clinical Trials Program), University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hong D; Department of Investigational Cancer Therapeutics (A Phase I Clinical Trials Program), University of Texas MD Anderson Cancer Center, Houston, TX, USA., Fu S; Department of Investigational Cancer Therapeutics (A Phase I Clinical Trials Program), University of Texas MD Anderson Cancer Center, Houston, TX, USA., Naing A; Department of Investigational Cancer Therapeutics (A Phase I Clinical Trials Program), University of Texas MD Anderson Cancer Center, Houston, TX, USA., Rodon J; Department of Investigational Cancer Therapeutics (A Phase I Clinical Trials Program), University of Texas MD Anderson Cancer Center, Houston, TX, USA., Javle M; Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ajani JA; Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Raghav KP; Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Somaiah N; Department of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Mills GB; Knight Cancer Institute, Oregon Health Sciences University, Portland, OR, USA., Tsimberidou AM; Department of Investigational Cancer Therapeutics (A Phase I Clinical Trials Program), University of Texas MD Anderson Cancer Center, Houston, TX, USA., Zheng X; Department of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Chen K; Department of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Meric-Bernstam F; Department of Investigational Cancer Therapeutics (A Phase I Clinical Trials Program), University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Breast Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.; The Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Publikováno v:
NPJ precision oncology [NPJ Precis Oncol] 2024 Jul 31; Vol. 8 (1), pp. 166. Date of Electronic Publication: 2024 Jul 31.
Autor:
Gouda MA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston., Shunyakova J; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston., Naing A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston., Dumbrava E; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston., Hong DS; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston., Yuan Y; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston., Yang P; Department of Palliative, Rehabilitation, and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston., Myers A; Department of Diagnostic and Biomedical Sciences, School of Dentistry, The University of Texas Health Science Center at Houston, Houston, USA., Liang Y; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston., Peng J; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston., Karp D; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston., Tsimberidou AM; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston., Rodon J; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston., Yap TA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston., Piha-Paul SA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston., Meric-Bernstam F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston., Fu S; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston. Electronic address: siqingfu@mdanderson.org.
Publikováno v:
ESMO open [ESMO Open] 2024 Jun; Vol. 9 (6), pp. 103486. Date of Electronic Publication: 2024 Jun 08.
Autor:
Luo J; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts., Sanchez M; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Lee E; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Hertzler H; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts., Luong N; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts., Mazzola E; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Finstein B; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Tamen R; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Brisbane G; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Nguyen T; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Paik PK; Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Chaft JE; Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Cheng ML; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts., Khalil H; Department of Thoracic Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts., Piha-Paul SA; Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas., Sholl LM; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts., Nishino M; Department of Radiology, Brigham and Women's Hospital, Boston, Massachusetts; Department of Imaging, Dana-Farber Cancer Institute, Boston, Massachusetts., Jänne PA; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts., DuBois SG; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts; Department of Pediatrics, Harvard Medical School, Boston, Massachusetts., Hanna GJ; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; Center for Head and Neck Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Shapiro GI; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; Center for Cancer Therapeutic Innovation, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., French CA; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. Electronic address: cfrench@bwh.harvard.edu.
Publikováno v:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2024 May; Vol. 19 (5), pp. 829-838. Date of Electronic Publication: 2023 Dec 27.
Autor:
Piha-Paul SA; Department of Investigational Cancer Therapeutics, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Xu B; Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China., Dumbrava EE; Department of Investigational Cancer Therapeutics, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Fu S; Department of Investigational Cancer Therapeutics, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Karp DD; Department of Investigational Cancer Therapeutics, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Meric-Bernstam F; Department of Investigational Cancer Therapeutics, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Hong DS; Department of Investigational Cancer Therapeutics, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Rodon JA; Department of Investigational Cancer Therapeutics, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Tsimberidou AM; Department of Investigational Cancer Therapeutics, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Raghav K; Department of Gastrointestinal Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Ajani JA; Department of Gastrointestinal Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Conley AP; Department of Sarcoma Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Mott F; Department of Thoracic and Head and Neck Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Fan Y; Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China., Fan J; Clinical Department, TransThera Sciences (US), Inc., Gaithersburg, MA, USA., Peng P; Project Management Department, TransThera Sciences (Nanjing), Inc., Nanjing, People's Republic of China., Wang H; Clinical Department, TransThera Sciences (Nanjing), Inc., Nanjing, People's Republic of China., Ni S; Drug Metabolism and Pharmacokinetics Department, TransThera Sciences (Nanjing), Inc., Nanjing, People's Republic of China., Sun C; Clinical Department, TransThera Sciences (Nanjing), Inc., Nanjing, People's Republic of China., Qiang X; Biology Department, TransThera Sciences (Nanjing), Inc., Nanjing, People's Republic of China., Levin WJ; Clinical Department, CRC Oncology, San Diego, CA, USA., Ngo B; Clinical Department, CRC Oncology, San Diego, CA, USA., Ru QC; Clinical Department, CRC Oncology, San Diego, CA, USA., Wu F; Project Management Department, TransThera Sciences (Nanjing), Inc., Nanjing, People's Republic of China.; Drug Metabolism and Pharmacokinetics Department, TransThera Sciences (Nanjing), Inc., Nanjing, People's Republic of China., Javle MM; Department of Gastrointestinal Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Publikováno v:
The oncologist [Oncologist] 2024 Apr 04; Vol. 29 (4), pp. e514-e525.
Autor:
Nelson BE; Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA. benelson1@mdanderson.org., Roszik J; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ahmed J; Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Barretto CMN; Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Nardo M; Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Campbell E; Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Johnson AM; Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Piha-Paul SA; Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Oliva ICG; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Weathers SP; Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Cabanillas M; Department of Endocrinology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Javle M; Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Meric-Bernstam F; Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Subbiah V; Early-Phase Drug Development, Sarah Cannon Research Institute, Nashville, TN, USA. Vivek.Subbiah@scri.com.
Publikováno v:
Molecular cancer [Mol Cancer] 2024 Mar 26; Vol. 23 (1), pp. 64. Date of Electronic Publication: 2024 Mar 26.
Autor:
Falchook G; Sarah Cannon Research Institute at HealthONE, Denver, Colorado., Patnaik A; START San Antonio, San Antonio, Texas., Richardson DL; Gynecologic Oncology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma; Sarah Cannon Research Institute, Oklahoma City, Oklahoma., Harvey RD; Emory University School of Medicine, Atlanta, Georgia., Sharma MR; START Midwest, Grand Rapids, Michigan., Hafez N; Yale Cancer Center, New Haven, Connecticut., Hamilton E; Sarah Cannon Research Institute at Tennessee Oncology, Nashville, Tennessee., Piha-Paul SA; Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas., Barve M; Mary Crowley Cancer Research Center, Dallas, Texas., Wise-Draper T; University of Cincinnati Cancer Center, Cincinnati, Ohio., Patel MR; Florida Cancer Specialists, Sarasota, Florida; Sarah Cannon Research Institute, Sarasota, Florida., Dowlati A; University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, Ohio., Pascuzzo J; Medical Oncology, California Cancer Associates for Research and Excellence, San Diego, California., Tang SC; Cancer Center and Research Institute, University of Mississippi Medical Center, Jackson, Mississippi., Faltermeier C; Pharmacokinetics, IQVIA, Kansas City, Missouri., Malinowska IA; Oncology Clinical Development, GSK, Waltham, Massachusetts., Shtessel L; Oncology Clinical Development, GSK, Waltham, Massachusetts., Striha A; Plus-Project Partnership Ltd, Knutsford, UK., Potocka E; Clinical Pharmacology Modeling and Simulation, GSK, Waltham, Massachusetts. Electronic address: ella.x.potocka@gsk.com.
Publikováno v:
Clinical therapeutics [Clin Ther] 2024 Mar; Vol. 46 (3), pp. 228-238. Date of Electronic Publication: 2024 Feb 28.
Autor:
Subbiah V; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Coleman N; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Piha-Paul SA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Tsimberidou AM; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Janku F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Rodon J; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Pant S; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Dumbrava EEI; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Fu S; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Hong DS; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Zhang S; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Sun M; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Jiang Y; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Roszik J; Department of Biostatistics, MD Anderson Cancer Center, Houston, Texas., Song J; Department of Biostatistics, MD Anderson Cancer Center, Houston, Texas., Yuan Y; Department of Biostatistics, MD Anderson Cancer Center, Houston, Texas., Meric-Bernstam F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Khalifa Institute for Personalized Cancer Therapy, MD Anderson Cancer Center, Houston, Texas.; Department of Surgical Oncology, MD Anderson Cancer Center, Houston, Texas., Naing A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Publikováno v:
Cancer research communications [Cancer Res Commun] 2024 Feb 12; Vol. 4 (2), pp. 378-387.
Autor:
Coleman N; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Stephen B; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Fu S; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Karp D; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Subbiah V; Early Phase Drug Development, Sarah Cannon Research Institute, Nashville, Tennessee, USA., Ahnert JR; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Piha-Paul SA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Wright J; National Cancer Institute (NCI), Cancer Therapy Evaluation Program (CTEP), Bethesda, Maryland, USA., Fessahaye SN; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Ouyang F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Yilmaz B; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Meric-Bernstam F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Khalifa Institute for Personalized Cancer Therapy, MD Anderson Cancer Center, Houston, Texas, USA.; Department of Surgical Oncology, MD Anderson Cancer Center, Houston, Texas, USA., Naing A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Publikováno v:
Cancer medicine [Cancer Med] 2024 Feb; Vol. 13 (3), pp. e6877.